Tardive dyskinesia and atypical antipsychotic drugs

Daniel Casey

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.

Original languageEnglish (US)
JournalSchizophrenia Research
Volume35
Issue numberSUPPL.
DOIs
StatePublished - Mar 1 1999
Externally publishedYes

Fingerprint

Antipsychotic Agents
Tardive Dyskinesia
Therapeutics
Mentally Ill Persons
Mood Disorders
Diabetes Mellitus
Central Nervous System
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Atypical antipsychotics
  • Clozapine
  • Extrapyramidal symptoms
  • Olanzapine
  • Risperidone
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Tardive dyskinesia and atypical antipsychotic drugs. / Casey, Daniel.

In: Schizophrenia Research, Vol. 35, No. SUPPL., 01.03.1999.

Research output: Contribution to journalArticle

Casey, Daniel. / Tardive dyskinesia and atypical antipsychotic drugs. In: Schizophrenia Research. 1999 ; Vol. 35, No. SUPPL.
@article{81f26f0e46524ba4b05a8f9c5286d4e0,
title = "Tardive dyskinesia and atypical antipsychotic drugs",
abstract = "Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.",
keywords = "Atypical antipsychotics, Clozapine, Extrapyramidal symptoms, Olanzapine, Risperidone, Tardive dyskinesia",
author = "Daniel Casey",
year = "1999",
month = "3",
day = "1",
doi = "10.1016/S0920-9964(98)00160-1",
language = "English (US)",
volume = "35",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "SUPPL.",

}

TY - JOUR

T1 - Tardive dyskinesia and atypical antipsychotic drugs

AU - Casey, Daniel

PY - 1999/3/1

Y1 - 1999/3/1

N2 - Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.

AB - Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs.

KW - Atypical antipsychotics

KW - Clozapine

KW - Extrapyramidal symptoms

KW - Olanzapine

KW - Risperidone

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0033104913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033104913&partnerID=8YFLogxK

U2 - 10.1016/S0920-9964(98)00160-1

DO - 10.1016/S0920-9964(98)00160-1

M3 - Article

VL - 35

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - SUPPL.

ER -